Masimo Shares Up 28.2% Past Six Months, Trades at 5.74 P/S Ratio
Masimo shares gained 28.2% over the past six months, outpacing Koninklijke Philips’ 17.8% rise but trailing Owlet’s 53.2% surge. The company trades at a forward 12-month price-to-sales ratio of 5.74, compared with the industry average of 8.31.
1. Recent Share Performance
Masimo shares rose 28.2% over the past six months, outperforming Koninklijke Philips’ 17.8% gain but trailing Owlet’s 53.2% surge. The 28.2% increase contrasts with iRhythm Technologies’ 24.3% decline, underscoring Masimo’s relative strength in medical monitoring devices.
2. Valuation Metrics
Masimo trades at a forward 12-month price-to-sales ratio of 5.74, below the industry average of 8.31 but above peers iRhythm’s 1.39 and Owlet’s 1.5. This mid-range valuation implies moderate investor expectations for revenue growth.
3. Peer Comparison
Relative to its peers, Masimo’s combination of solid share gains and a mid-tier P/S ratio positions it as a stable performer in the medical device sector. Upcoming product rollouts and regulatory approvals will be critical to maintaining its competitive edge.